Targeting tumor necrosis factor α in IBD allows intestinal healing by blocking TNFR1-dependant intestinal epithelial cell death [2] and inducing cell death in macrophages by binding to transmembrane TNF or by depriving TNFR2-dependent CD4+ T cell survival via NF-κB activation [3]. The gene discussed is TNF; the disease is inflammatory bowel disease.